Besides its metabolic role, PGAM1 can also interact with α-smooth muscle actin (ACTA2) to enhance tumor growth and metastasis and overcome erlotinib resistance in non-small-cell lung cancer (NSCLC) 19. Here, ACTA2 is linked to non-small cell lung carcinoma.